Myelin Oligodendrocyte Glycoprotein-Associated Pediatric Central Nervous System Demyelination: Clinical Course, Neuroimaging Findings, and Response to Therapy

Neuropediatrics

Volumn 47, Issue 4, 2016, Pages 245-252

  Thulasirajah, Salini ^a   Pohl, Daniela ^a   Davila Acosta, Jorge ^a   Venkateswaran, Sunita ^a  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

demyelination; MOG; multiple sclerosis; optic neuritis; transverse myelitis

Indexed keywords

IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; STEROID; AUTOANTIBODY; GLUCOCORTICOID; IMMUNOLOGIC FACTOR;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ANAPHYLACTOID PURPURA; ARTICLE; ATAXIA; BABINSKI REFLEX; BACKACHE; BLADDER DYSFUNCTION; BRAIN DISEASE; BRAIN STEM; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CHILDHOOD DISEASE; CLONUS; COLOR VISION; CONSTIPATION; COUGHING; DEMYELINATION; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; ELECTROENCEPHALOGRAPHY; ENCEPHALITIS; FEMALE; FEVER; FOLLOW UP; GAIT; GAIT DISORDER; HEAD INJURY; HEADACHE; HUMAN; INFLAMMATORY DISEASE; IRRITABILITY; LEG PAIN; LIMB WEAKNESS; MALE; MEDICAL HISTORY; MOUTH ULCER; MYELITIS; NAUSEA; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE; OPTIC NEURITIS; PERCEPTION DEAFNESS; PHYSICAL EXAMINATION; PLEOCYTOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RHINORRHEA; SCHOOL CHILD; SLURRED SPEECH; STEROID THERAPY; TREATMENT RESPONSE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VISUAL ACUITY; VISUAL IMPAIRMENT; VOMITING; WHITE MATTER; BRAIN; DEMYELINATING DISEASES; DIAGNOSTIC IMAGING; ENCEPHALOMYELITIS, ACUTE DISSEMINATED; IMMUNOLOGY; MYELITIS, TRANSVERSE; NEUROMYELITIS OPTICA; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SPINAL CORD; TREATMENT OUTCOME;

AUTOANTIBODIES; BRAIN; CHILD; CHILD, PRESCHOOL; DEMYELINATING DISEASES; ENCEPHALOMYELITIS, ACUTE DISSEMINATED; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; MYELITIS, TRANSVERSE; NEUROMYELITIS OPTICA; RETROSPECTIVE STUDIES; SPINAL CORD; TREATMENT OUTCOME;

EID: 84964655362     PISSN: 0174304X     EISSN: 14391899     Source Type: Journal    
DOI: 10.1055/s-0036-1583184     Document Type: Article

References (32)

1. Mayer M. C., Meinl E. Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more. Ther Adv Neurol Disord: 2012; 5 3 147 159
2. Lennon V. A., Wingerchuk D. M., Kryzer T. J., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet: 2004; 364 9451 2106 2112
3. Pröbstel A-K, Rudolf G., Dornmair K., et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation: 2015; 12 1 46
4. Martinez-Hernandez E., Sepulveda M., Rostásy K., et al. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis. JAMA Neurol: 2015; 72 2 187 193
5. Ramanathan S., Reddel S. W., Henderson A., et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm: 2014; 1 4 e40 e40
6. Hacohen Y., Absoud M., Deiva K., et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm: 2015; 2 2 e81
7. Saadoun S., Waters P., Owens G. P., Bennett J. L., Vincent A., Papadopoulos M. C. Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun: 2014; 2 1 35
8. Gao J., Pan W., Zhang H. Features of neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies. JAMA Neurol: 2014; 71 7 923 924
9. Cobo-Calvo Á, Sepúlveda M., Bernard-Valnet R., et al. Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: Clinical and prognostic implications. Mult Scler: 2016; 22 3 312 319
10. Tanaka M., Tanaka K. Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system. J Neuroimmunol: 2014; 270 1-2 98 99
11. Waters P., Woodhall M., O'Connor K. C., et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm: 2015; 2 3 e89 e89
12. Aktas O. Collateral benefit: the comeback of MOG antibodies as a biomarker in neurological practice. J Neurol Neurosurg Psychiatry: 2015; 86 3 243 243
13. Willison H. J., Linington C. Antibodies to MOG in NMO: a seasoned veteran finds a new role. Neurology: 2012; 79 12 1198 1199
14. Höftberger R., Sepulveda M., Armangue T., et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler: 2015; 21 7 866 874
15. Reindl M., Di Pauli F., Rostásy K., Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol: 2013; 9 8 455 461
16. Rostasy K., Mader S., Schanda K., et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol: 2012; 69 6 752 756
17. Pröbstel A. K., Dornmair K., Bittner R., et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology: 2011; 77 6 580 588
18. Brilot F., Dale R. C., Selter R. C., et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol: 2009; 66 6 833 842
19. Ketelslegers I. A., Van Pelt D. E., Bryde S., et al. Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort. Mult Scler: 2015; 21 12 1513 1520
20. Di Pauli F., Mader S., Rostasy K., et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin Immunol: 2011; 138 3 247 254
21. Kitley J., Waters P., Woodhall M., et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol: 2014; 71 3 276 283
22. Mader S., Gredler V., Schanda K., et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation: 2011; 8 184
23. Huppke P., Rostasy K., Karenfort M., et al. Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients. Mult Scler: 2013; 19 7 941 946
24. Kitley J., Woodhall M., Waters P., et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology: 2012; 79 12 1273 1277
25. Lechner C., Baumann M., Hennes E-M., et al. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatry: 2015
26. Baumann M., Sahin K., Lechner C., et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry: 2015; 86 3 265 272
27. Krupp L. B., Tardieu M., Amato M. P., et al. International Pediatric Multiple Sclerosis Study Group. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler: 2013; 19 10 1261 1267
28. Tsuburaya R. S., Miki N., Tanaka K., et al. Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in a Japanese boy with recurrent optic neuritis. Brain Dev: 2015; 37 1 145 148
29. Sato D. K., Callegaro D., Lana-Peixoto M. A., et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology: 2014; 82 6 474 481
30. Hacohen Y., Absoud M., Woodhall M., et al. UK & Ireland Childhood CNS Inflammatory Demyelination Working Group. Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort. J Neurol Neurosurg Psychiatry: 2014; 85 4 456 461
31. Spadaro M., Gerdes L. A., Mayer M. C., et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol: 2015; 2 3 295 301
32. Di Pauli F., Höftberger R., Reindl M., et al. Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology. Neurol Neuroimmunol Neuroinflamm: 2015; 2 6 e175